Table 2.

Results for secondary composite endpoints. Data are expressed as percentages of patients.

	Sumatriptan/naproxen sodium (n = 726)	Sumatriptan (n=723)	Naproxen sodium (n = 720)	Placebo (n=742)
Sustained pain-free/no adverse events within 1 day	17∗	11	10	7
Sustained pain-free/no drug-related adverse events within up to 5 days	21∗	14	10	7
Sustained pain-free/no drug-related adverse events within 1 day	21∗	14	10	7
Sustained pain relief/no adverse events within up to 5 days	31†	24	25	15
Sustained pain relief/no adverse events within 1 day	32∗	24	25	16

^∗p<0.001 versus sumatriptan, naproxen sodium, and placebo.

^†p<0.001 versus sumatriptan and placebo and p<0.005 versus naproxen sodium.